Extended Data Fig. 8: Mean Score Change from Baseline of EORTC QLQ-C30 Global Health Status/Quality of Life Score at Each Cycle in Patients in TRK TKI-Naïve and TRK TKI-Pretreated Cohorts.
From: Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial
Abbreviations: European Organisation for Research and Treatment of Cancer (EORTC), tyrosine kinase inhibitor (TKI), tropomyosin receptor kinase (TRK).
